Categories
Change Password!
Reset Password!
Tegoprazan demonstrates rapid acid suppression and superior nocturnal symptom control, strengthening its potential as an effective alternative to proton pump inhibitors in GERD.
Persistent reflux symptoms continue to affect many patients with gastroesophageal reflux disease (GERD) despite standard proton pump inhibitor (PPI) therapy. Nocturnal acid breakthrough, non-erosive reflux disease (NERD), and variable treatment response remain important clinical challenges, highlighting the need for therapies that provide faster and more sustained acid control.
A systematic review and meta-analysis evaluated whether tegoprazan, a potassium-competitive acid blocker (PCAB), could improve clinical outcomes across GERD and related acid-mediated disorders. The review analysed evidence from 18 clinical studies, comparing tegoprazan with PPIs across efficacy, symptom control, Helicobacter pylori eradication, and safety outcomes.
The findings revealed several clinically relevant benefits:
Overall, tegoprazan offered more than effective acid suppression. Its rapid onset of action, improved overnight symptom control, favourable tolerability, and additional benefits in H. pylori eradication positioned it as a clinically relevant PCAB option and supported its expanding role in the management of GERD and other acid-mediated gastrointestinal disorders.
JGH Open
Tegoprazan in Gastroesophageal Reflux Disease and Related Acid‐Mediated Conditions: A Systematic Review and Meta‐Analysis
Sanjay Bandyopadhyay et al.
Comments (0)